Paliperidone Extended-Release Tablets Suppliers & Bulk Manufacturers
Available Forms: Extended-Release Tablets
Available Strengths: 1.5 mg, 3 mg, 6 mg, 9 mg
Reference Brands: Invega®(US & EU)
Category:
Antipsychotropic Drugs
Paliperidone is an atypical antipsychotic that works by blocking dopamine D2 and serotonin 5-HT2A receptors, helping to reduce symptoms of schizophrenia and improve mood stability. The extended-release (ER) tablets use an OROS delivery system to provide steady plasma levels over 24 hours, minimizing fluctuations and side effects. They are used for the treatment of schizophrenia and schizoaffective disorder in adults.
Paliperidone Extended-Release Tablets is available in Extended-Release Tablets
and strengths such as 1.5 mg, 3 mg, 6 mg, 9 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Paliperidone Extended-Release Tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Paliperidone Extended-Release Tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Paliperidone extended-release tablets (brand name: Invega) are FDA-approved in the United States for the treatment of schizophrenia and schizoaffective disorder in adults. In the European Union, they are authorized under the centralized procedure for schizophrenia. Regulatory requirements include GMP-compliant manufacturing, osmotic-controlled release oral delivery system (OROS) data, and comprehensive clinical efficacy and safety studies. The product labeling in the U.S. includes a boxed warning for increased mortality in elderly patients with dementia-related psychosis. EU authorization also mandates Risk Management Plans (RMPs) and post-marketing safety monitoring. To explore dossier-ready Paliperidone ER tablets, visit Pharmatradz.com.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing